To retrospectively analyze the safety and efficacy of low dose rituximab regimen in patients with Epstein-Barr virus (EBV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Among 12 cases, 11 achieved complete remission (CR), 1 with partial remission (PR). Patients received 15 infusions with a median of 2.5(1-4) in each. The EBV DNA negative transformation period was 5-25 days with median 12 days. Low dose rituximab could be an alternative choice in patients with EBV infection after allo-HSCT.
回顾性分析小剂量利妥昔单抗治疗异基因造血干细胞移植后EB病毒（EBV）感染相关性疾病的疗效及安全性。所有患者均顺利完成治疗。结果显示，12例患者中，部分缓解（PR) 1例，完全缓解（CR) 11例。12例患者应用利妥昔单抗15例次，中位值为2.5(1~4）例次；EBV DNA转阴时间为5~25 d，中位值为12 d。对于异基因造血干细胞移植术后EBV感染相关性疾病患者，小剂量利妥昔单抗治疗安全、有效。.
Keywords: Allogeneic haematopoietic stem cell transplantation; Epstein-Barr virus; Rituximab.